Simplex Trading’s Avalo Therapeutics AVTX Stock Holding History

Simplex Trading’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342K	Sell	18,500 -31,200	-63%	-$493K	﹤0.01%	4070
2026 Q1	$742K	Buy	49,700 +31,600	+175%	+$494K	﹤0.01%	2816
2025 Q4	$329K	Buy	18,100 +12,700	+235%	+$214K	﹤0.01%	3720
2025 Q3	$68K	Buy	5,400 +1,400	+35%	+$12K	﹤0.01%	6138
2025 Q2	$19K	Buy	+4,000	New	+$18.7K	﹤0.01%	6797
2023 Q1	–	Sell	-1	Closed	-$1K	–	8985
2022 Q4	$1K	Buy	+1	New	+$1.3K	﹤0.01%	8751
2022 Q3	–	Sell	-4	Closed	-$6K	–	9864
2022 Q2	$6K	Buy	+4	New	+$5.35K	﹤0.01%	8694
2022 Q1	–	Sell	-1	Closed	-$5K	–	10352
2021 Q4	$5K	Buy	+1	New	+$6K	﹤0.01%	9489
2021 Q3	–	Sell	-6	Closed	-$59K	–	9754
2021 Q2	$59K	Buy	+6	New	+$50.3K	﹤0.01%	7441
2021 Q1	–	Hold	0	–	–	–	7029
2019 Q1	–	Hold	0	–	-$1K	–	7110
2018 Q4	–	Hold	0	–	–	–	6701
2018 Q3	–	Hold	0	–	-$4K	–	7378
2018 Q2	–	Hold	0	–	–	–	6784

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Simplex Trading's AVTX Position: Q4 2025 in Review

Simplex Trading sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 748 shares — an estimated $12.6K sold.

Simplex Trading first reported a position in AVTX in Q1 2021 and held it in 4 quarters. The position peaked at $94K in Q4 2021. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

Simplex Trading reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
Simplex Trading sold 748 Avalo Therapeutics shares in Q4 2025, an estimated $12.6K.
Simplex Trading first reported a position in Avalo Therapeutics in Q1 2021 and held it in 4 quarters.
Simplex Trading's Avalo Therapeutics position peaked at $94K in Q4 2021.
84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.